AbbVie's Temab-A gets two FDA breakthrough designations
AbbVie says the U.S. FDA granted Telisotuzumab Adizutecan (Temab-A) breakthrough therapy designations for CRC and NSCLC.
Story updates
12:30:49 PM UTC
SquawkNews
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
12:48:10 PM UTC
SquawkNews
Abbvie's Telisotuzumab Adizutecan Receives Two Breakthrough Therapy Designations From The U.S. FDA For Crc And Nsclc